Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of the National Cancer Institute |
Vol/bind | 112 |
Udgave nummer | 9 |
Sider (fra-til) | 964–967 |
ISSN | 0027-8874 |
DOI | |
Status | Udgivet - 2020 |
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492759/pdf/djz217.pdf
Forlagets udgivne version
ID: 237753930